Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?
暂无分享,去创建一个
D. Symmons | L. Hooper | K. Payne | R. Elliott | R A Elliott | L Hooper | K Payne | T J Brown | C Roberts | D Symmons | T. Brown | C. Roberts | Tamara Brown | Rachel Elliott | Katherine Payne | Lee Hooper | Chris Roberts | D. Symmons
[1] Douglas G Altman,et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.
[2] J. Gornbein,et al. Clinical and economic outcomes of individuals with severe peptic ulcer hemorrhage and nonbleeding visible vessel: an analysis of two prospective clinical trials , 1998, American Journal of Gastroenterology.
[3] S. Morant,et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use , 1997, Alimentary pharmacology & therapeutics.
[4] Sebastian Schneeweiss,et al. Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.
[5] M. Sculpher,et al. Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.
[6] S. Kong,et al. Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom , 2001 .
[7] Carol Coupland,et al. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.
[8] J. Dieleman,et al. Underutilization of preventive strategies in patients receiving NSAIDs. , 2003, Rheumatology.
[9] Emily R. Cox,et al. PARI I: VERIFICATION OF A DECISION ANALYTIC MODEL ASSUMPTION USING REAL WORLD PRACTICE DATA: IMPLICATIONS FORTHE COST-EFFECTIVENESS OF COX-2S , 2003 .
[10] Ann Netten,et al. Unit Costs of Health and Social Care 2002 , 2000 .
[11] A. Kubba,et al. Upper gastro-intestinal disease in Scotland: a survey of practice amongst Scottish gastroenterologists. , 1996, Journal of the Royal College of Surgeons of Edinburgh.
[12] D. Symmons,et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review , 2004, BMJ : British Medical Journal.
[13] J. Dieleman,et al. Adherence to proton pump inhibitors or H2‐receptor antagonists during the use of non‐steroidal anti‐inflammatory drugs , 2003, Alimentary pharmacology & therapeutics.
[14] C. Bombardier,et al. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. , 1998, Arthritis and rheumatism.
[15] R. Russell,et al. Predicting NSAID related ulcers--assessment of clinical and pathological risk factors and importance of differences in NSAID. , 1994, Gut.
[17] S. Hill,et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis , 1996, BMJ.
[18] L. G. García Rodríguez,et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. , 1998, Archives of internal medicine.
[19] R. Makuch,et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.
[20] V. Strand,et al. Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis , 2004, American journal of therapeutics.
[21] T. MacDonald,et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study , 1997, BMJ.
[22] M. Ebell,et al. Evaluation of the dyspeptic patient: a cost-utility study. , 1997, The Journal of family practice.
[23] D. Symmons,et al. systematic review by non-steroidal anti-inflammatory drugs: prevention of gastrointestinal toxicity induced The effectiveness of five strategies for the , 2005 .
[24] G. Hankey,et al. Cyclooxygenase-2 Inhibitors: Are They Really Atherothrombotic, and If Not, Why Not? , 2003, Stroke.
[25] C. Patrono,et al. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. , 2003, Arthritis and rheumatism.
[26] Lise,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[27] A. Sonnenberg,et al. Health impact of peptic ulcer in the United States. , 1997, The American journal of gastroenterology.
[28] G. Dagenais,et al. Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein: A Randomized Placebo-Controlled Study , 2004, Circulation.
[29] T. Lieu,et al. Quality Of Life Measurement Clarifies The Cost-Effectiveness Of Helicobacter Pylori Eradication In Peptic Ulcer Disease And Uninvestigated Dyspepsia , 2001, American Journal of Gastroenterology.
[30] K. Palmer,et al. Non-variceal upper gastrointestinal haemorrhage: guidelines , 2002, Gut.
[31] S. Hernández-Díaz,et al. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. , 2000, Archives of internal medicine.
[32] L. Curtis,et al. Unit Costs of Health and Social Care 2016 , 2015 .